Group 1 - The core viewpoint indicates that the stock of XGIMI Technology (688696) is currently showing a weak overall score of 35.52, suggesting a cautious investment outlook [1] - The main cost analysis reveals that the current main cost is 110.50 CNY, with a 5-day average cost of 106.83 CNY, a 20-day average of 112.82 CNY, and a 60-day average of 118.03 CNY, indicating a downward trend in costs over time [1] - The stock has not experienced any limit-up or limit-down events in the past year, reflecting a stable trading environment [1] Group 2 - The technical analysis shows a short-term resistance level at 112.52 CNY and a support level at 105.12 CNY, while the mid-term resistance is at 120.53 CNY with the same support level [2] - The current short-term and mid-term trends are unclear, with a need for main funds to choose a direction [2] - On July 11, 2025, the net inflow of main funds was 944.91 million CNY, accounting for 9% of the total transaction volume, indicating a positive sentiment among larger investors [2]

航宇科技688239 时间: 2025年7月11日星期五 58.37分综合得分 较强 趋势方向 主力成本分析 元 33.91 元 当日主力成本 33.69 元 5日主力成本 33.01 元 20日主力成本 31.83 60日主力成本 周期内涨跌停 过去一年内该股 涨停 0次 跌停 0 次 北向资金数据 | 持股量63.79万股 | 占流通比0.44% | | --- | --- | | 昨日净买入-3.75万股 | 昨日增仓比-0.026% | | 5日增仓比-0.006% | 20日增仓比0.117% | 技术面分析 33.11 短期支撑位 34.98 中期压力位 30.77 中期支撑位 目前短线趋势不慎明朗，静待主力资金选择方向； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 暂无特殊形态 资金流数据 34.28 短期压力位 财务数据 最近的财报数据显示，该股于2025年07月11日 | 每股收益0.29元 | 营业利润0.51亿元 | | --- | --- | | 市盈率--- | 销售毛利率26.229% | | 净利润46,368,800.57元 | | 2025年7月11日星期五 58. ...

Group 1 - The stock of Olin Bio (688319) has a comprehensive score of 49.71, indicating a weak performance [1] - The main cost analysis shows the following prices: current main cost at 16.28 CNY, 5-day main cost at 16.07 CNY, 20-day main cost at 16.33 CNY, and 60-day main cost at 16.09 CNY [1] - There have been no instances of the stock hitting the upper or lower limit in the past year [1] Group 2 - On July 4, 2025, the net outflow of main funds was 14.08 million CNY, accounting for -17% of the total transaction amount [2] - The stock's short-term resistance is at 16.60 CNY, while the short-term support is at 15.66 CNY [2] - The recent financial report indicates a net profit of -7,041,533.34 CNY and an operating profit of -0.07 billion CNY, with a sales gross margin of 93.43% [2][3] Group 3 - The stock is associated with sectors such as bioproducts (0.38%), biovaccines (0.30%), innovative drugs (1.18%), and the western development sector (-0.53%) [2][3] - The stock is currently experiencing unclear short-term and mid-term trends, awaiting direction from main funds [2][3]

A股三大指数今日涨跌不一，截至收盘，沪指涨0.32%，深成指跌0.25%，创业板指跌0.36%，北证50指数跌1.88%。全市场成交额 14545亿元，较上日放量1210亿元。全市场超4100只个股下跌。 板块题材上，跨境支付、银行、游戏、电力、钢铁、创新药板块涨幅居前；固态电池、有色金属、美容护理、风电设备板块跌幅居 前。 盘面上，银行板块集体走高，中信银行、浦发银行、上海银行（601229）多股创出历史新高。创新药概念股反复活跃，广生堂 （300436）连续2日20cm涨停，塞力医疗（603716）走出4连板。跨境支付板块表现积极，信雅达（600571）、京北方（002987）涨 停。固态电池概念股集体下挫，信宇人大跌10%，华盛锂电、金银河（300619）跌幅居前。风电设备板块表现低迷，吉鑫科技 （601218）盘中跌停，大金重工（002487）、泰胜风能（300129）跟跌。有色金属板块午后持续下跌，精艺股份（002295）跌停，北 方铜业（000737）、广晟有色（600259）跌幅靠前。 涨停天梯榜： 【4连板】 柳钢股份（601003）、塞力医疗。 【3连板】 亚玛顿（002623）。 【2连板 ...

大全能源688303 时间: 2025年7月3日星期四 趋势方向 主力成本分析 23.17 元 当日主力成本 21.74 元 5日主力成本 68.57分综合得分 较强 19.80 元 20日主力成本 19.23 元 60日主力成本 周期内涨跌停 过去一年内该股 涨停 19.86 短期支撑位 2次 跌停 0 次 北向资金数据 持股量2794.62万股 占流通比5.05% 昨日净买入-19.39万股 昨日增仓比-0.035% 5日增仓比0.01% 20日增仓比0.069% 技术面分析 23.75 短期压力位 23.75 中期压力位 18.39 中期支撑位 目前短线趋势不慎明朗，静待主力资金选择方向； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 暂无特殊形态 资金流数据 2025年07月03日的资金流向数据方面 主力资金净流出5664.33万元 占总成交额-8% 超大单净流出5045.57万元 大单净流出618.76万元 散户资金净流入76.80万 关联行业/概念板块 光伏设备 0.02%、半导体概念 0.57%、太阳能 0.40%、西部大开发 0.46%等 财务数据 最近的财报数据显示，该股于2025年 ...

极米科技688696 43.64分综合得分 偏弱 趋势方向 主力成本分析 115.24 元 当日主力成本 114.25 元 时间: 2025年6月26日星期四 5日主力成本 118.20 元 20日主力成本 120.15 元 60日主力成本 周期内涨跌停 0 次 北向资金数据 | 持股量40.46万股 | 占流通比0.57% | | --- | --- | | 昨日净买入-0.82万股 | 昨日增仓比-0.012% | | 5日增仓比-0.102% | 20日增仓比-0.039% | 技术面分析 117.00 短期压力位 过去一年内该股 涨停 0次 跌停 112.06 短期支撑位 124.10 中期压力位 112.06 中期支撑位 目前短线趋势不慎明朗，静待主力资金选择方向； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 暂无特殊形态 资金流数据 2025年06月26日的资金流向数据方面 | 主力资金净流出582.15万元 | | --- | | 占总成交额-12% | | 超大单净流出638.33万元 | | 大单净流入56.18万元 | | 散户资金净流出78.14万 | 关联行业/概念板块 家电 ...

Group 1 - The stock of Kangtuo Medical (688314) has a comprehensive score of 47.79, indicating a weak performance [1] - The main cost analysis shows the following prices: current main cost at 29.70 yuan, 5-day main cost at 29.24 yuan, 20-day main cost at 30.09 yuan, and 60-day main cost at 29.18 yuan [1] - Over the past year, the stock has not experienced any limit-up or limit-down events [1] Group 2 - The short-term pressure level is at 29.63 yuan, while the short-term support level is at 28.33 yuan [2] - The stock price has the potential to strengthen in the short term if it breaks through the short-term pressure level, but the mid-term trend remains unclear [2] - The K-line pattern indicates heavy pressure at the upper levels, with a long upper shadow suggesting resistance, while the "red three soldiers" pattern indicates a possible bottoming out and recovery [2] Group 3 - On June 26, 2025, the net inflow of main funds was 160.69 thousand yuan, accounting for 6% of the total transaction amount [2] - There was no net inflow from super large orders, while large orders contributed a net inflow of 160.69 thousand yuan, and retail investors saw a net inflow of 62.30 thousand yuan [2] - Related industry sectors showed mixed performance, with medical devices down by 0.55% and the medical device concept down by 0.46% [2]

XSJ!1!2025060142!08-02!218525 公开发行 可转换 公司 债券 资产 负债 率［ 权益 资本 与刚性 债 务比率【 」 流动 比率 ［ 现金 比率 【 利息 保障倍 数「 倍］ 净资产 收益 率［ 经 营性 现金 净流入 量与 流动 负债 比率 ［ 非 筹 资 性现 金 净 流 入 量 与 负 债 总 额 比率 ［ %］ 年 度 发 行人本 次评 级模 型分析 表 与模 商企 业评 级方法 与 模型 建筑 施 行业 结果 业务 风险 财务 风险 初始 信用 级别 合计 调整 子 级数 量 个体 信用 其中 ① 调 整 因素 ④ 其他 因素 个 体信 用级 别 外部 支持 支持 因 素 主 体信 用级 别 调整 因素 (0) 无 支持 因素 (0) 无 注 个体 信用级 别 跟踪 期内 公 司 基 本 消除 相 关事件 产生 的 不利 彩响 公 司个体信 用级 别 由 调 整至 外 部支持 外 部 支 持 提 升 子级 为 在 该 公 司 个 体 信 用 级 别 墓 础 卜实 际 使 用 的 外 部 支 持 力 度 相关评级技术文件及研究资料 相关技术文件与研究资料名称 链接 《新世纪 ...

Core Viewpoint - The western region of China is experiencing significant economic growth and development, with a focus on enhancing its industrial ecosystem and promoting high-quality development through strategic initiatives and regional cooperation [1][2][12]. Economic Growth and Development - In 2024, the western region's GDP reached 287.35 billion yuan, marking a growth of 5.2% [1]. - The GDP of the western region increased from 11.39 trillion yuan in 2012 to 28.7 trillion yuan in 2024, with its share of the national GDP rising from 19.8% to 21.3% [2]. - The Chengdu-Chongqing economic circle is a key driver of growth, contributing approximately 30.3% to the western region's GDP in 2024 [2]. Industrial Development - The western region is focusing on developing characteristic advantageous industries and modernizing its industrial system to enhance competitiveness [3]. - Traditional industries such as energy, equipment manufacturing, and agriculture are being upgraded with modern technology, leading to increased quality and efficiency [3]. - By the end of 2023, the total installed capacity of renewable energy in the western region exceeded 400 million kilowatts, accounting for about 40% of the national total [3]. Rural Revitalization - The western region is integrating poverty alleviation efforts with rural revitalization, focusing on developing local industries to boost income for residents and tax revenue for governments [4]. - The black goat industry in Chongqing's Dazu District exemplifies successful local industry development, generating over 1 billion yuan in comprehensive output [4]. Future Industry Layout - The western region is strategically planning for future industries by promoting the integration of technological and industrial innovation [5]. - Collaborative efforts are being made to enhance cross-regional integration of innovation and industry chains, particularly in emerging sectors like artificial intelligence and quantum technology [5]. Ecological Protection and Sustainable Development - The western region plays a crucial role in national ecological security, with significant efforts being made to balance ecological protection with economic development [6][7]. - The region is implementing major ecological restoration projects, with 35,000 hectares of ecological restoration completed by the end of 2024 [8]. Open Economy and Trade - The western region is enhancing its openness to promote economic development, establishing free trade zones and fostering cross-border economic cooperation [12][13]. - The number of China-Europe freight trains has significantly increased, facilitating trade and logistics between the western region and international markets [15]. Social Development and Quality of Life - Since the implementation of the western development strategy, residents' disposable income has increased from 24,000 yuan in 2019 to 31,000 yuan in 2023 [17]. - The region has made strides in education and healthcare, with improvements in health indicators and educational attainment levels [18][20]. Challenges and Future Directions - Despite progress, challenges such as income disparity, urbanization levels, and public service availability remain in the western region [21]. - Future efforts will focus on leveraging ecological resources, enhancing urbanization, and improving public services to meet the needs of residents [21].

行业报告 | 行业专题研究 建筑装饰 证券研究报告 西部基建专题：固投高景气，关注重大基建项目带来 的区域投资机会 西部固投高景气，专项债发行提速+战略规划落地对后续基建支撑作用更强 24 年以来西部固投增速高增，25M1-4 内蒙古、新疆、西藏等仍然保持两 位数增长。从资金端来看，25 年中西部区域的新增专项债明显提速，其中 四川同比+162%、重庆同比+35%、陕西同比+1162%，化债省份中贵州、云 南、西藏等均有所增长。今年 2 万亿再融资专项置换债已落地超 80%，后续 置换债券发行节奏放缓将为专项债券发行腾出空间，而专项债券对基建的支 撑作用更大，后续债券发行对基建支撑作用将更强。西部资源禀赋好，战略 上承接产业转移，自 19 年对新时代推进西部大开发形成新格局作出部署以 来，西部地区的 GDP19-24 年复合增速达 7%，25 年西部各省 GDP 计划增速 中，仅有青海目标低于全国水平，西藏 25 年 GDP 计划超过 7%、力争 8%， 领跑全国，西部地区经济持续健康发展，给基建投资增长提供较好基础。随 着中央财政的持续加码和国家战略规划的落地，未来西部地区的基建景气度 或仍有较强支撑。此外 ...